{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:38:27Z","timestamp":1779248307743,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11606-017-4280-y","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T20:33:23Z","timestamp":1516394003000},"page":"551-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Diagnosis and Management of Hepatitis C Infection in Primary Care Settings"],"prefix":"10.1007","volume":"33","author":[{"given":"Debra","family":"Guss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagannath","family":"Sherigar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smruti R.","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"issue":"6","key":"4280_CR1","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"H Razavi","year":"2013","unstructured":"Razavi H, ElKhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164-70.","journal-title":"Hepatology."},{"key":"4280_CR2","unstructured":"Centers for Disease Control & Prevention. Hepatitis C FAQs for Health Professionals 2008. Available from: https:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm Retrieved September 15, 2017."},{"issue":"17","key":"4280_CR3","first-page":"453","volume":"64","author":"JE Zibbell","year":"2015","unstructured":"Zibbell JE, Iqbal K, Patel R, Suryaprasad A, Sanders K, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged \u2264 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453-8.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"4280_CR4","doi-asserted-by":"crossref","unstructured":"Williford SE, McGivern DR. Mechanism of Action of Direct-Acting Antivirals: New Insights into the HCV Life Cycle. In: Miyamura T, Lemon S, Walker C, Wakita T, eds. Hepatitis C Virus II. Tokyo: Springer; 2016:287-301.","DOI":"10.1007\/978-4-431-56101-9_11"},{"key":"4280_CR5","unstructured":"US Food and Drug Administration. Hepatitis B and C Treatments. 2017. Available from: https:\/\/www.fda.gov\/ForPatients\/Illness\/HepatitisBC\/ucm408658.htm . Retrieved July 14, 2017."},{"issue":"9742","key":"4280_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705-16.","journal-title":"Lancet."},{"key":"4280_CR7","doi-asserted-by":"crossref","unstructured":"Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19(2).","DOI":"10.1111\/j.1365-2893.2011.01528.x"},{"issue":"1","key":"4280_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.27826","volume":"62","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Bourli\u00e8re M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015;62(1):79-86.","journal-title":"Hepatology."},{"issue":"4","key":"4280_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1053\/j.gastro.2015.07.001","volume":"149","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015;149(4):971\u201380. e1.","journal-title":"Gastroenterology"},{"issue":"7","key":"4280_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1086\/428578","volume":"40","author":"AL Cox","year":"2005","unstructured":"Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis. 2005;40(7):951-8.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"4280_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"H Aasld-Idsa","year":"2015","unstructured":"Aasld-Idsa H. Guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54.","journal-title":"Hepatology."},{"issue":"1","key":"4280_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"J Micallef","year":"2006","unstructured":"Micallef J, Kaldor J, Dore G. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34-41.","journal-title":"J Viral Hepat."},{"issue":"5","key":"4280_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/j.1572-0241.2008.01825.x","volume":"103","author":"SM Kamal","year":"2008","unstructured":"Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008;103(5):1283-97.","journal-title":"Am J Gastroenterol."},{"key":"4280_CR14","doi-asserted-by":"crossref","unstructured":"D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 44(1):217\u201331.","DOI":"10.1016\/j.jhep.2005.10.013"},{"issue":"1","key":"4280_CR15","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1):S58-S68.","journal-title":"J Hepatol."},{"key":"4280_CR16","doi-asserted-by":"crossref","unstructured":"Reilley B. Birth Cohort Testing for Hepatitis C Virus\u2014Indian Health Service 2012\u20132015. MMWR Morb Mortal Wkly Rep. 2016;65(18):467\u20139.","DOI":"10.15585\/mmwr.mm6518a3"},{"issue":"9","key":"4280_CR17","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/cid\/cis011","volume":"54","author":"PO Coffin","year":"2012","unstructured":"Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54(9):1259-71.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"4280_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","volume":"77","author":"A Chan","year":"2017","unstructured":"Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017;77(2):131-44.","journal-title":"Drugs."},{"key":"4280_CR19","doi-asserted-by":"crossref","unstructured":"Isaura Cunha M, Maria Lucia Gomes F, Renata Mello P, Christine Takemi E, Silvia Naomi de Oliveira U, Roberto Jos\u00e9 de C-F, et al. Do differences exist between chronic hepatitis C genotypes 2 and 3? Rev Soc Bras Med Trop. 2014;(2):143.","DOI":"10.1590\/0037-8682-0269-2013"},{"issue":"1","key":"4280_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, et al. Grazoprevir\u2013Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015;163(1):1-13.","journal-title":"Ann Intern Med."},{"issue":"20","key":"4280_CR21","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-88.","journal-title":"N Engl J Med."},{"issue":"27","key":"4280_CR22","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599-607.","journal-title":"N Engl J Med."},{"issue":"9956","key":"4280_CR23","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-65.","journal-title":"Lancet."},{"issue":"17","key":"4280_CR24","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-603.","journal-title":"N Engl J Med."},{"issue":"4","key":"4280_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-35.","journal-title":"Hepatology."},{"key":"4280_CR26","unstructured":"Hassanein TI, Wyles DL, Wang S, Kwo PY, Shiffman ML, Younes Z, et al., eds. Glecaprevir\/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4). In vitro. 2016;2:3."},{"key":"4280_CR27","first-page":"2","volume":"1","author":"DL Wyles","year":"2016","unstructured":"Wyles DL, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. SURVEYOR-II, part 3: efficacy and safety of glecaprevir\/pibrentasvir (ABT-493\/ABT-530) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and\/or cirrhosis. In Vitro. 2016;1:2.","journal-title":"In Vitro."},{"key":"4280_CR28","first-page":"1","volume":"64","author":"M Bourliere","year":"2016","unstructured":"Bourliere M, Gordon SC, Ramji A, Ravendhran N, Tran TT, Hyland RH, et al. Sofosbuvir\/Velpatasvir\/Voxilaprevir for 12 weeks as a Salvage regimen in NS5A inhibitor-experienced patients with genotype 1\u20136 infection: the phase 3 POLARIS-1 study. Hepatology. 2016;64:1\u2013136.","journal-title":"Hepatology."},{"issue":"2","key":"4280_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ajg.2011.314","volume":"107","author":"ML Volk","year":"2012","unstructured":"Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2012;107(2):247-52.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"4280_CR30","first-page":"218","volume":"25","author":"V Papastergiou","year":"2012","unstructured":"Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol. 2012;25(3):218.","journal-title":"Ann Gastroenterol."},{"issue":"1","key":"4280_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.24654","volume":"55","author":"J Boursier","year":"2012","unstructured":"Boursier J, De Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55(1):58-67.","journal-title":"Hepatology."},{"issue":"4","key":"4280_CR32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.","journal-title":"J Hepatol."},{"issue":"3","key":"4280_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.","journal-title":"Hepatology."},{"issue":"2","key":"4280_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","volume":"4","author":"M Omata","year":"2010","unstructured":"Omata M, Lesmana LA, Tateishi R, Chen P-J, Lin S-M, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439-74.","journal-title":"Hepatol Int."},{"issue":"2","key":"4280_CR35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.21037\/tcr.2017.03.80","volume":"6","author":"DA Guss","year":"2017","unstructured":"Guss DA, Mohanty SR. Integrative review: patient and provider factors related to hepatocellular carcinoma surveillance in patients with liver cirrhosis. Transl Lung Cancer Res. 2017;6(2):450-6.","journal-title":"Transl Lung Cancer Res."},{"issue":"6","key":"4280_CR36","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1053\/gast.2002.33419","volume":"122","author":"DM Jensen","year":"2002","unstructured":"Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology. 2002;122(6):1620-30.","journal-title":"Gastroenterology."},{"key":"4280_CR37","doi-asserted-by":"crossref","first-page":"S377-S","DOI":"10.14309\/00000434-201610001-00864","volume":"111","author":"V Gayam","year":"2016","unstructured":"Gayam V, Mukhtar O, Khalid M, Garlapati P, Sherigar J, Khan A, et al. Direct Acting Antivirals in HIV-HCV Co-infection: A Community Based Retrospective Cohort Study. Am J Gastroenterol. 2016;111:S377-S.","journal-title":"Am J Gastroenterol"},{"issue":"suppl_1","key":"4280_CR38","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/cid\/ciw219","volume":"63","author":"DL Wyles","year":"2016","unstructured":"Wyles DL, Sulkowski MS, Dieterich D. Management of hepatitis C\/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy. Clin Infect Dis. 2016;63(suppl_1):S3-S11.","journal-title":"Clin Infect Dis"},{"issue":"suppl_1","key":"4280_CR39","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1093\/cid\/ciw220","volume":"63","author":"CE MacBrayne","year":"2016","unstructured":"MacBrayne CE, Kiser JJ. Pharmacologic considerations in the treatment of hepatitis C virus in persons with HIV. Clin Infect Dis. 2016;63(suppl_1):S12-S23.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4280_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000456585","volume":"35","author":"S Lens","year":"2017","unstructured":"Lens S, Rodriguez-Tajes S, Llovet L-P, Maduell F, Londo\u00f1o M-C. Treating Hepatitis C in Patients with Renal Failure. Dig Dis. 2017;35(4):339-46.","journal-title":"Dig Dis."},{"issue":"5","key":"4280_CR41","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.kint.2016.01.011","volume":"89","author":"F Fabrizi","year":"2016","unstructured":"Fabrizi F, Martin P, Messa P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89(5):988-94.","journal-title":"Kidney Int."},{"issue":"1","key":"4280_CR42","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8278(17)30269-6","volume":"66","author":"X Forns","year":"2017","unstructured":"Forns X, Lee S, Valdes J, Lens S, Ghalib R, Aguilar H, et al. GS-006-EXPEDITION-I: efficacy and safety of glecaprevir\/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis. J Hepatol. 2017;66(1):S3-S4.","journal-title":"J Hepatol."},{"issue":"7","key":"4280_CR43","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150(7):1590-8.","journal-title":"Gastroenterology."},{"key":"4280_CR44","doi-asserted-by":"crossref","unstructured":"Sherigar JM, Gayam V, Khan A, Mukhtar O, Arefiev Y, Khalid M, et al. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2017;29(7):767\u20136","DOI":"10.1097\/MEG.0000000000000871"},{"issue":"2","key":"4280_CR45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/jgs.13928","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Nader F, Henry L. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon-and Ribavirin-Free Regimens. J Am Geriatr Soc. 2016;64(2):386-93.","journal-title":"J Am Geriatr Soc."},{"issue":"16","key":"4280_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/14740338.2017.1325869","volume":"3","author":"JA Holmes","year":"2017","unstructured":"Holmes JA, Yu M-L, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy\u2013implication for susceptible individuals. Expert Opin Drug Saf. 2017;Jun 3(16):651\u201372.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"4280_CR47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/00034983.1999.11813480","volume":"93","author":"C Pramoolsinsap","year":"1999","unstructured":"Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol. 1999;93(7):745-51.","journal-title":"Ann Trop Med Parasitol."},{"key":"4280_CR48","unstructured":"Centers for Disease Control. Recommended Immunization Schedules http:\/\/www.cdc.gov\/vaccines\/vdp-vac\/vpd-list.htm . Retrieved March 16, 2017."},{"issue":"6","key":"4280_CR49","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","volume":"149","author":"DJ Back","year":"2015","unstructured":"Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149(6):1315-7.","journal-title":"Gastroenterology."},{"issue":"1","key":"4280_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hep.27366","volume":"61","author":"EM Yoshida","year":"2015","unstructured":"Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Ratziu V, Ding X, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41-5.","journal-title":"Hepatology."},{"issue":"6","key":"4280_CR51","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1053\/j.gastro.2017.03.018","volume":"152","author":"IM Jacobson","year":"2017","unstructured":"Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update\u2014Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152(6):1578-87.","journal-title":"Gastroenterology."},{"issue":"58.2","key":"4280_CR52","first-page":"59","volume":"58","author":"SM Kattakuzhy","year":"2016","unstructured":"Kattakuzhy SM. High Efficacy of HCV Treatment by Primary Care Providers: The ASCEND Study. Age. 2016;58(58.2):59.","journal-title":"Age"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-017-4280-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-017-4280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-017-4280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T16:05:28Z","timestamp":1570637128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-017-4280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["4280"],"URL":"https:\/\/doi.org\/10.1007\/s11606-017-4280-y","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"8 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Smruti Mohanty is a speaker and advisor for Gilead, AbbVie, and Merck. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}